Despite its clear superiority over Fetal Bovine Serum (FBS) for clinical applications, the Human Platelet Lysate (HPL) market faces critical challenges related to scalability and standardization, which act as adoption barriers, particularly for large-scale biomanufacturing. HPL is derived from human platelets, meaning its supply is inherently dependent on blood donation volume and logistics....
فارسی
English
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Arabic